Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs Johnson & Johnson (JNJ) Price & Performance

Edgewise Therapeutics Inc. Common StockTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Edgewise Therapeutics Inc. Common Stock vs Johnson & Johnson — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while Johnson & Johnson trades at $258 (market cap $599.12B). The key difference: Johnson & Johnson is far larger — about 152.1× Edgewise Therapeutics Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.16% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.

EWTXJNJ
Market Cap
$3.94B$599.12B
Volume
810,10416,640,951
Sector
HealthHealth
52-Week High
$48.35$278.43
52-Week Low
$14.89$186.00
Typical Hold Time
0 Days129 Days
Enterprise Value
$3.48B$627.40B
Dividend Yield
—2.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Edgewise Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Johnson & Johnson

JNJ trades at $253.91, down 3.72% on the day, amid a mixed technical and fundamental backdrop. The stock shows strong profitability with a 21.48% net income margin and 25.74% ROE, supported by three consecutive quarterly EPS beats. Analyst consensus is bullish with a $282.73 price target, though recent news highlights competitive pressures and patent cliff concerns. Cash flow trends indicate robust operations but elevated investing outflows.

The outlook remains positive given JNJ's diversified healthcare portfolio and innovation pipeline, but investors face risks from debt levels rising to 24.06% of assets and biosimilar competition. Near-term resistance lies at $265, with support at $257. Institutional sentiment favors growth in pharmaceuticals and medical technology, though macroeconomic and regulatory headwinds persist.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWTX
100% Buy0% Sell
Avg holding period · 0 Days
JNJ
84% Buy16% Sell
Avg holding period · 129 Days

Top news

Latest headlines on both assets

About Edgewise Therapeutics Inc. Common Stock

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.

Read more on EWTX →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ →